

# Clinical Policy: FEHB Fertility Preservation



Reference Number: QCP.CP.042  
Effective Date: 01/01/2023  
Date of Last Revision: 09/01/2024

CPT® Codes:  
Document: BI701:00

## Public Statement

This policy is specific to the Federal Employees Health Benefits.

Male and female fertility may be transiently or permanently affected by medical treatments such as gonadotoxic therapy, cytotoxic chemotherapy, or radiation therapy, as well as by other iatrogenic causes. Rates of permanent infertility and compromised fertility after medical treatment vary and depend on many factors, including the drug, size and location of the radiation field if applicable, dose, dose-intensity, method of administration (oral versus intravenous), disease, age, treatment type and dosages, and pretreatment fertility.

Storage is limited to one (1) year and benefits are limited to one cycle of fertility preservation per covered person during the entire period the member is enrolled with QualChoice.

## Effective Date:

## Medical Statement

- I. Any of the following procedures are **medically necessary** for women and adolescent girls prior to commencing treatment that is likely to cause infertility (excluding voluntary sterilization):
  - A. Embryo cryopreservation;
  - B. Cryopreservation of mature oocytes;
  - C. Ovarian transposition (oophoropexy);
  - D. Radiation (gonadal) shielding;
  - E. Infertility associated with medical and surgical gender transition treatment.
  - F. Conservative gynecologic surgery including but not limited to the following:
    1. Radical trachelectomy in early stage cervical cancer (i.e., stage IA2 to IB cervical cancer with diameter <2 cm and invasion <10 mm);
    2. Ovarian cystectomy for early-stage ovarian cancer.
- II. The following procedures are **medically necessary** for men and adolescent boys prior to commencing treatment that is likely to cause infertility (excluding voluntary sterilization):
  - A. Cryopreservation of sperm;
  - B. Radiation (gonada) shielding.
  - C. Infertility associated with medical and surgical gender transition treatment.

# Clinical Policy: FEHB Fertility Preservation



- III. Procedures for women and adolescent girls prior to commencing treatment that is likely to affect fertility are considered **investigational**:
  - A. Cryopreservation of immature oocytes;
  - B. Ovarian tissue cryopreservation and transplantation procedures;
  - C. Ovarian suppression with gonadotropin releasing hormone (GnRHa) or antagonists.
  
- IV. It is the policy of health plans affiliated with Centene Corporation that the following procedures for men and adolescent boys prior to commencing treatment that is likely to affect fertility are considered **investigational**:
  - A. Testicular suppression with GnRHa or antagonists'
  - B. Testicular tissue or spermatogonial cryopreservation
  - C. Re-implantation or grafting of human testicular tissue.

### Codes Used In This BI:

|       |  |
|-------|--|
| 00840 | Anesthesia for intraperitoneal procedures in lower abdomen including laparoscopy; not otherwise specified  |
| 57531 | Radical trachelectomy, with bilateral total pelvic lymphadenectomy and para-aortic lymph node sampling biopsy, with or without removal of tube(s), with or without removal of ovary(s) |
| 58825 | Transposition, ovary(s)  |
| 58970 | Follicle Puncture for oocyte retrieval, any method   |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete  |
| 76948 | Ultrasonic guidance for aspiration of ova, imaging supervision and interpretation  |
| 77334 | Treatment devices, design and construction, complex (irregular blocks, special shields, compensators, wedges, molds or casts)  |
| 82670 | Estradiol  |
| 83001 | Gonadotropin; follicle stimulating hormone (FSH)   |
| 83002 | Gonadotropin; luteinizing hormone (LH)   |
| 84144 | Progesterone   |
| 84702 | Gonadotropin; chorionic (hCG); quantitative  |
| 89250 | Culture of oocyte(s)/embryo(s), less than 4 days   |
| 89251 | Culture of oocyte(s)/embryo(s), less than 4 days; with co-culture of oocyte(s)/embryos   |
| 89254 | Oocyte identification from follicular fluid  |
| 89258 | Cryopreservation, embryo(s) (freezing services, not storage)   |
| 89259 | Cryopreservation; sperm  |
| 89268 | Insemination of oocytes  |
| 89272 | Extended culture of oocytes/embryo(s), 4-7 days  |

# Clinical Policy: FEHB Fertility Preservation



|       |   |
|-------|---|
| 89280 | Assisted oocyte fertilization, microtechnique; less than or equal to 10 oocytes   |
| 89281 | Assisted oocyte fertilization, microtechnique; greater than 10 oocytes  |
| 89320 | Semen analysis; volume, count motility and differential   |
| 89337 | Cryopreservation, mature oocyte(s)  |
| 89352 | Thawing of cryopreserved; embryo(s)   |
| 89353 | Thawing of cryopreserved; sperm/semens, each aliquot  |
| 99000 | Handling and/or conveyance of specimen for transfer from office to a laboratory   |
| 99001 | Handling and/or conveyance of specimen for transfer from the patient in other than an office to a laboratory (distance may be indicated)  |
| 99070 | Supplies and materials (except spectacles), provided by the physician or other qualified health care professional over and above those usually included with the office visit or other services rendered (list drugs, trays, supplies, or materials provided) |
| 99078 | Physician or other qualified health care professional qualified by education, training, licensure/regulation (when applicable) educational services in a group setting (eg, prenatal, obesity, or diabetic instructions)                                      |
| 99199 | Unlisted special service, procedure or report   |

| HCPCS Codes | Description   |
|-------------|---|
| S4030       | Sperm procurement and cryopreservation services; initial visit    |
| S4031       | Sperm procurement and cryopreservation services; subsequent visit |

| CPT Codes Considered Investigational |   |
|--------------------------------------|---|
| CPT® Codes                           | Description                                       |
| 89335                                | Cryopreservation, reproductive tissue, testicular |
| 0058T                                | Cryopreservation; reproductive tissue, ovarian    |

| ICD-10-CM Diagnosis Codes that Support Coverage Criteria |  |
|--|--|
| ICD 10 CM Code   | Description                                    |
| C00.0-D49  | Neoplasms                                      |
| D27.0  | Benign neoplasm of right ovary                 |
| D27.1  | Benign neoplasm of left ovary                  |
| D39.10-D39.12  | Neoplasm of uncertain behavior of ovary        |
| D40.10-D40.12  | Neoplasm of uncertain behavior of testis       |
| N70.01-N70.03  | Acute salpingitis and oophoritis               |
| N70.11-N70.13  | Chronic salpingitis and oophoritis             |
| N83.511-N83.519  | Torsion of ovary and ovarian pedicle           |
| Z31.84   | Encounter for fertility preservation procedure |

## Background

The most frequent cause of impaired fertility in male cancer survivors is chemotherapy or radiation-induced damage to sperm. The fertility of female survivors may be impaired by any treatment that damages immature eggs, affects the body's hormonal balance, or injures the reproductive organs. Fertility preservation is an essential part of the management of adolescents and young adults who are at risk for infertility due to cancer treatments, or bilateral ovary or testicular removal for treatment of disease.

Embryo cryopreservation is an established fertility preservation method, and it has routinely been used for storing surplus embryos after in vitro fertilization. Cryopreservation of unfertilized oocytes is an option, particularly for patients who do not have a male partner, do not wish to use donor sperm, or have religious or ethical objections to embryo freezing. Success rates for this procedure have improved significantly, with some reproductive specialty centers reporting success rates comparable to those obtained using unfrozen eggs, especially in younger women. Like embryo cryopreservation, this technique also requires ovarian stimulation and ultrasound-guided oocyte retrieval.

The effectiveness of ovarian suppression with GnRHa or antagonists is inconclusive. There is conflicting evidence to recommend GnRHa as a method of fertility preservation. Studies to date have not provided definitive data demonstrating that GnRHa preserves fertility, and it remains the subject of ongoing research.

### ***American Society of Clinical Oncology (ASCO)***

ASCO's recommends discussing fertility preservation with all patients of reproductive age (and with parents or guardians of children and adolescents) if infertility is a potential risk of therapy, as early as possible, before treatment starts.

For males who express an interest in fertility preservation, sperm cryopreservation is the only established fertility preservation method. ASCO notes that hormonal therapy in men has not shown to be successful in preserving fertility. Per ASCO, other methods, including testicular tissue cryopreservation for the purpose of future re-implantation or grafting of human testicular tissue are experimental.

For females who express an interest in fertility preservation, both embryo and oocyte cryopreservation are established fertility preservation methods. Other options for women include ovarian transposition (oophoroexy) when pelvic radiation therapy for cancer treatment is performed or conservative gynecological surgery and radiation options. ASCO notes that ovarian tissue cryopreservation for the purpose of future transplantation is experimental. They note also, there is insufficient evidence regarding the effectiveness of ovarian suppression (gonadotropin-releasing hormone analogs) to preserve fertility.

The ASCO guidelines continue to note that there is conflicting evidence to recommend GnRHa and other means of ovarian suppression for fertility preservation. However, the Panel

recognizes that, when proven fertility preservation methods are not feasible, and in the setting of young women with breast cancer, GnRHa may be offered to patients in the hope of reducing the likelihood of chemotherapy-induced ovarian insufficiency. GnRHa should not be used in place of proven fertility preservation methods. The panel notes that the field of ovarian tissue cryopreservation is advancing quickly and may evolve to become standard therapy in the future, although at the time of publication, it remains experimental.<sup>10</sup>

For children, ASCO recommends using established methods of fertility preservation (semen cryopreservation and oocyte cryopreservation) for post pubertal minor children, with patient assent, if appropriate, and parent or guardian consent.<sup>1</sup> For pre-pubertal children, the only fertility preservation options are ovarian and testicular cryopreservation, which are investigational.<sup>10</sup>

### ***National Comprehensive Cancer Network (NCCN)***

NCCN guidelines on Adolescent and Young Adult Oncology note that mature oocyte cryopreservation is no longer considered investigational, however, embryo cryopreservation is preferred if there is an identified sperm donor.<sup>2</sup>

Ovarian tissue cryopreservation is a promising, but less well-studied strategy for female fertility preservation when there is insufficient time for oocyte or embryo cryopreservation and/or the patient is pre-pubertal. While tissue cryopreservation is still considered investigational at some institutions, it may be discussed as an option for fertility preservation.<sup>2</sup>

Some data suggest that menstrual suppression with GnRHa may protect ovarian function. However, evidence that menstrual suppression with GnRHa protect ovarian function is insufficient, so this procedure is not currently recommended as an option for fertility preservation.<sup>2</sup>

### ***American College of Obstetricians and Gynecologists (ACOG)***

For young women who have completed sexual development, GnRHa, such as leuprolide acetate, have been used to induce ovarian quiescence to preserve ovarian function and fertility after cytotoxic treatment. Leuprolide acetate is not recommended for pre-pubertal girls. There still is no conclusive evidence that demonstrates efficacy of GnRHa, and studies are primarily observational regarding their effectiveness in fertility preservation. The use of GnRHa should be considered and discussed with premenopausal patients who will be treated with chemotherapeutic agents. Because GnRHa have mixed results in fertility preservation with trends toward more favorable outcomes, GnRHa therapy may be recommended as an adjuvant to chemotherapy. A meta-analysis of females 14–45 years of age demonstrated that co-treatment with GnRH agonists during chemotherapy was associated with increased odds of maintaining ovarian function and achieving pregnancy after treatment.<sup>11</sup>

### **Coding Implications**

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2019, American Medical Association. All rights reserved. CPT codes and CPT descriptions are

from the current manuals and those included herein are not intended to be all- inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

## Reference

1. Loren AW1, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol*. 2013 Jul 1;31(19):2500-10. Available at: <http://jco.ascopubs.org/content/early/2013/05/24/JCO.2013.49.2678.full.pdf>
2. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Adolescent and young adult (AYA) oncology. Update May 30, 2019. Version 1.2020.
3. American College of Obstetricians and Gynecologists (ACOG). Committee Opinion No. 584. Oocyte cryopreservation. Committee Opinion No. 584. January 2014. Reaffirmed 2018.
4. American College of Obstetricians and Gynecologists (ACOG) Committee Number 607, Gynecologic Concerns in Children and Adolescents With Cancer. August 2014. Reaffirmed 2017. Replaced by Committee Opinion No.747
5. Practice Committee of American Society for Reproductive Medicine. Ovarian tissue cryopreservation: a committee opinion. *Fertil Steril*. 2014 May;101(5):1237-43
6. Pfeifer S, Goldberg J, McClure R, et al. Mature oocyte cryopreservation: a guideline. Practice Committees of American Society for Reproductive Medicine; Society for Assisted Reproductive Technology. *Fertil Steril*. 2013 Jan;99(1):37-43
7. Shah JS, Guerra R, Bodurka DC, et al. Factors influencing fertility-sparing treatment for gynecologic malignancies: A survey of Society of Gynecologic Oncology members. *Gynecol Oncol*. 2017 Sep 21. pii: S0090-8258(17)31343-4
8. Hayes Technology Brief. Ovarian Tissue Cryopreservation for Preservation of Fertility in Patients Undergoing Gonadotoxic Cancer Treatment. Dec 2016. Update Nov 8, 2018.
9. Pacheco F, Oktay K. Current Success and Efficiency of Autologous Ovarian Transplantation: A Meta-Analysis. *Reprod Sci*. 2017 Aug;24(8):1111-1120. doi: 10.1177/1933719117702251
10. Oktay K, Harvey BE, Partridge AH, et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. *J Clin Oncol*. 2018 Jul 1;36(19):1994-2001. doi:

# Clinical Policy: FEHB Fertility Preservation



10.1200/JCO.2018.78.1914. Available at:

<https://ascopubs.org/doi/pdf/10.1200/JCO.2018.78.1914>

11. American College of Obstetricians and Gynecologists (ACOG) Committee Number 747. Gynecologic Issues in Children and Adolescent Cancer Patients and Survivors. August 2018. (Replaces Committee Opinion Number 607, August 2014)
12. Sonmezer M, Oktay K. Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection. In: UpToDate, Barbieri RL (Ed), UpToDate, Accessed Aug 28, 2019. Updated Jul 24, 2019.

## Addendums:

### Application to Products

This policy applies to all health plans and products administered by QualChoice, both those insured by QualChoice and those that are self-funded by the sponsoring employer, unless there is indication in this policy otherwise or a stated exclusion in your medical plan booklet. Consult the individual plan sponsor Summary Plan Description (SPD) for self-insured plans or the specific Evidence of Coverage (EOC) or Certificate of Coverage (COC) for those plans or products insured by QualChoice. In the event of a discrepancy between this policy and a self-insured customer's SPD or the specific QualChoice EOC or COC, the SPD, EOC, or COC, as applicable, will prevail. State and federal mandates will be followed as they apply.

QualChoice reserves the right to alter, amend, change or supplement medical policies as needed. QualChoice reviews and authorizes services and substances. CPT and HCPCS codes are listed as a convenience and any absent, new or changed codes do not alter the intent of the policy.